Expanded recall for Franck's Compounds

The FDA is notifying all physicians and healthcare organizations of the recall of all sterile products sold by Franck's Compounding Pharmacy since November 2011 due to the possibility of lack of sterility.

In March 19, 2012, FDA received reports of fungal endophthalmitis in patients who were given Brilliant Blue G (BBG), supplied by Franck's Pharmacy, during eye surgeries. In April 20, 2012, FDA received reports of eye infections in patients who were given injections of Franck's drug products containing triamcinolone acetonide during eye surgery.

An active investigation by the CDC and FDA is ongoing at this time. FDA advises that any product received from Franck's since November 2011 not be used.

For more information visit http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305592.htm.

More in Web Exclusives

Stroke costs expected to double by 2030

Stroke costs expected to double by 2030

Higher stroke prevalence in an aging population brings total projected stroke costs to $240.67 billion by 2030.

Fish oil may benefit insulin sensitivity

Fish oil may benefit insulin sensitivity

Long-chain fatty acids in fish oil boost circulating adiponectin levels.

Most clinicians not trained to ID medication nonadherence

Most clinicians not trained to ID medication nonadherence

Approximately 30% to 50% of U.S adults do not adhere to long-term medications.